Our research investigates the importance of interactions between the gut microbiome, diet and the developing immune system in early life. This is an exciting new frontier for human health.
The microbiome educates our immune system
From the moment we are born, our bodies begin to be colonised by trillions of bacteria, fungi and viruses, collectively known as microbiota. Our immune system is developing in parallel, so a baby's gut is the site of dynamic cross-talk between the microbiota and the immune system.
Once we reach adulthood, 70–80 percent of our immune cells reside in the gut. How this vital and interactive environment, the diet-microbiota-immune axis, develops during the first years of life.
Our Translational Immunology team investigates the microbiome’s influence on the development of an optimal immune system and aims to identify potential links with non-communicable diseases such as asthma, allergy, obesity, cardiovascular disease and cancer.
Our Translational Immunology team is led by Dr Olivier Gasser with research in two programmes – infectious disease and inflammatory disease.
The infectious disease programme is investigating animal and human antibody responses to flu vaccines.
Our inflammatory disease research is in the following areas:
- Allergic disease in the skin, lung and gut. We are deciphering the immune mechanisms for novel targets that treat and prevent allergic disease. We are also studying the role of food to improve immune outcomes for allergy avoidance.
- Obesity: examining the relationship between the immune system and host metabolism.
- Gut inflammation: researching the mechanisms that regulate intestinal homeostasis and gut health.
Our nutrition & microbiome research requires the use of the Hugh Green Cytometry Core.